These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 12350250)
21. vFitness: a web-based computing tool for improving estimation of in vitro HIV-1 fitness experiments. Ma J; Dykes C; Wu T; Huang Y; Demeter L; Wu H BMC Bioinformatics; 2010 May; 11():261. PubMed ID: 20482791 [TBL] [Abstract][Full Text] [Related]
22. The contribution of HIV fitness to the evolution pattern of reverse transcriptase inhibitor resistance. Paintsil E; Margolis A; Collins JA; Alexander L J Med Virol; 2006 Apr; 78(4):425-30. PubMed ID: 16482556 [TBL] [Abstract][Full Text] [Related]
24. Modeling and estimation of kinetic parameters and replicative fitness of HIV-1 from flow-cytometry-based growth competition experiments. Miao H; Dykes C; Demeter LM; Cavenaugh J; Park SY; Perelson AS; Wu H Bull Math Biol; 2008 Aug; 70(6):1749-71. PubMed ID: 18648886 [TBL] [Abstract][Full Text] [Related]
25. In vivo dynamics of the 103N mutation following the withdrawal of non-nucleoside reverse transcriptase inhibitors in HIV-infected patients: preliminary results. Gianotti N; Boeri E; Maillard M; Serra G; Ratti D; Gallotta G; Vacchini D; Tremolada Y; Castagna A New Microbiol; 2004 Apr; 27(2 Suppl 1):111-7. PubMed ID: 15646073 [TBL] [Abstract][Full Text] [Related]
26. Impact of the HIV integrase genetic context on the phenotypic expression and in vivo emergence of raltegravir resistance mutations. Nguyen TT; Rato S; Molina JM; Clavel F; Delaugerre C; Mammano F J Antimicrob Chemother; 2015 Mar; 70(3):731-8. PubMed ID: 25336162 [TBL] [Abstract][Full Text] [Related]
27. Effects of replicative fitness on competing HIV strains. Chirove F; Lungu EM Biosystems; 2013 Jul; 113(1):28-36. PubMed ID: 23623939 [TBL] [Abstract][Full Text] [Related]
28. Relationship between drug resistance mutations, plasma viremia, and CD4+ T-cell counts in patients with chronic HIV infection. de Mendoza C; Martín-Carbonero L; Gallego O; Corral A; González-Lahoz J; Soriano V J Med Virol; 2005 May; 76(1):1-6. PubMed ID: 15778973 [TBL] [Abstract][Full Text] [Related]
29. Resistance and replication capacity assays: clinical utility and interpretation. Haubrich RH Top HIV Med; 2004; 12(2):52-6. PubMed ID: 15184711 [TBL] [Abstract][Full Text] [Related]
30. Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase. Murray JM; Emery S; Kelleher AD; Law M; Chen J; Hazuda DJ; Nguyen BY; Teppler H; Cooper DA AIDS; 2007 Nov; 21(17):2315-21. PubMed ID: 18090280 [TBL] [Abstract][Full Text] [Related]
31. T20-insensitive HIV-1 from naive patients exhibits high viral fitness in a novel dual-color competition assay on primary cells. Neumann T; Hagmann I; Lohrengel S; Heil ML; Derdeyn CA; Kräusslich HG; Dittmar MT Virology; 2005 Mar; 333(2):251-62. PubMed ID: 15721359 [TBL] [Abstract][Full Text] [Related]
32. [German-Austrian guidelines for antiretroviral therapy of HIV infection. (July, 2002, update)]. Brockmeyer NH; ; Dtsch Med Wochenschr; 2003 May; 128 Suppl 1():S7-18. PubMed ID: 12736863 [No Abstract] [Full Text] [Related]
33. Human immunodeficiency virus type 1 fitness and tropism: concept, quantification, and clinical relevance. Clementi M; Lazzarin A Clin Microbiol Infect; 2010 Oct; 16(10):1532-8. PubMed ID: 20678176 [TBL] [Abstract][Full Text] [Related]
34. High fidelity simian immunodeficiency virus reverse transcriptase mutants have impaired replication in vitro and in vivo. Lloyd SB; Lichtfuss M; Amarasena TH; Alcantara S; De Rose R; Tachedjian G; Alinejad-Rokny H; Venturi V; Davenport MP; Winnall WR; Kent SJ Virology; 2016 May; 492():1-10. PubMed ID: 26896929 [TBL] [Abstract][Full Text] [Related]
35. Isolation of drug-resistant mutant HIV variants using tissue culture drug selection. Oliveira M; Brenner BG; Wainberg MA Methods Mol Biol; 2009; 485():427-33. PubMed ID: 19020842 [TBL] [Abstract][Full Text] [Related]
36. Reduced viral fitness and lack of cross-class resistance with integrase strand transfer inhibitor and nucleoside reverse transcriptase inhibitor resistance mutations. Andreatta KN; Goodman DD; Miller MD; White KL Antimicrob Agents Chemother; 2015; 59(6):3441-9. PubMed ID: 25824231 [TBL] [Abstract][Full Text] [Related]
37. Evolutionary pathways of transmitted drug-resistant HIV-1. Pingen M; Nijhuis M; de Bruijn JA; Boucher CA; Wensing AM J Antimicrob Chemother; 2011 Jul; 66(7):1467-80. PubMed ID: 21502281 [TBL] [Abstract][Full Text] [Related]
38. Progressive reversion of human immunodeficiency virus type 1 resistance mutations in vivo after transmission of a multiply drug-resistant virus. Gandhi RT; Wurcel A; Rosenberg ES; Johnston MN; Hellmann N; Bates M; Hirsch MS; Walker BD Clin Infect Dis; 2003 Dec; 37(12):1693-8. PubMed ID: 14689353 [TBL] [Abstract][Full Text] [Related]
39. Mutation N155H in HIV-2 integrase confers high phenotypic resistance to raltegravir and impairs replication capacity. Salgado M; Toro C; Simón A; Garrido C; Blanco F; Soriano V; Rodés B J Clin Virol; 2009 Oct; 46(2):173-5. PubMed ID: 19625211 [TBL] [Abstract][Full Text] [Related]
40. Intra-host evolution of human immunodeficiency virus type 1 and viral fitness. Clementi M; Canducci F; Bagnarelli P; Menzo S New Microbiol; 2004 Apr; 27(2 Suppl 1):41-4. PubMed ID: 15646063 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]